These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 30030591)

  • 1. Inhibition of protein misfolding and aggregation by natural phenolic compounds.
    Dhouafli Z; Cuanalo-Contreras K; Hayouni EA; Mays CE; Soto C; Moreno-Gonzalez I
    Cell Mol Life Sci; 2018 Oct; 75(19):3521-3538. PubMed ID: 30030591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade.
    Chiti F; Dobson CM
    Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.
    Moreno-Gonzalez I; Soto C
    Semin Cell Dev Biol; 2011 Jul; 22(5):482-7. PubMed ID: 21571086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-polyphenolic natural inhibitors of amyloid aggregation.
    Ma L; Yang C; Zheng J; Chen Y; Xiao Y; Huang K
    Eur J Med Chem; 2020 Apr; 192():112197. PubMed ID: 32172082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies.
    Khan AN; Khan RH
    Int J Biol Macromol; 2022 Dec; 223(Pt A):143-160. PubMed ID: 36356861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prion-Like Protein Aggregates and Type 2 Diabetes.
    Mukherjee A; Soto C
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes as a protein misfolding disease.
    Mukherjee A; Morales-Scheihing D; Butler PC; Soto C
    Trends Mol Med; 2015 Jul; 21(7):439-49. PubMed ID: 25998900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling protein aggregation as an ageing related process or a neuropathological response.
    Trigo D; Nadais A; da Cruz E Silva OAB
    Ageing Res Rev; 2019 May; 51():67-77. PubMed ID: 30763619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models for prion-like diseases.
    Fernández-Borges N; Eraña H; Venegas V; Elezgarai SR; Harrathi C; Castilla J
    Virus Res; 2015 Sep; 207():5-24. PubMed ID: 25907990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro, and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice.
    Aitken JF; Loomes KM; Riba-Garcia I; Unwin RD; Prijic G; Phillips AS; Phillips ARJ; Wu D; Poppitt SD; Ding K; Barran PE; Dowsey AW; Cooper GJS
    Biochem Biophys Res Commun; 2017 Jan; 482(4):625-631. PubMed ID: 27865831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectral Fluorescence Pathology of Protein Misfolding Disorders.
    Stepanchuk AA; Stys PK
    ACS Chem Neurosci; 2024 Mar; 15(5):898-908. PubMed ID: 38407017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein folding and aggregation into amyloid: the interference by natural phenolic compounds.
    Stefani M; Rigacci S
    Int J Mol Sci; 2013 Jun; 14(6):12411-57. PubMed ID: 23765219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
    Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
    Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.
    Zaman M; Khan AN; Wahiduzzaman ; Zakariya SM; Khan RH
    Int J Biol Macromol; 2019 Aug; 134():1022-1037. PubMed ID: 31128177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
    Pain C; Dumont J; Dumoulin M
    Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermodynamic and kinetic approaches for drug discovery to target protein misfolding and aggregation.
    Vendruscolo M
    Expert Opin Drug Discov; 2023; 18(8):881-891. PubMed ID: 37276120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on protein misfolding, aggregation and strategies to prevent related ailments.
    Shamsi TN; Athar T; Parveen R; Fatima S
    Int J Biol Macromol; 2017 Dec; 105(Pt 1):993-1000. PubMed ID: 28743576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.